Sentinel on pace for 2027 flight test FALLS CHURCH, Va., Sept. 14, 2026 (GLOBE NEWSWIRE) — America’s next-generation intercontinental ballistic missile moved another step closer to defending the nation when Northrop Grumman (NYSE: NOC) and the U.S. Air Force fully assembled the Sentinel missile in its operational orientation. The vertical assembly demonstrates the design and integration of the missile and is a major step toward the Sentinel missile’s design and suitability evaluation for flight test in 2027. Sentinel is making progress toward fielding, a key part of the nation’s strategic deterrence.In partnership with the U.S. Air Force, Northrop Grumman engineers have completed the safe stacking of the Sentinel missile. This proves all missile stages, propulsion elements, the shroud, and associated components have been fully...

Exclusive South Bay townhome community opens for sale on September 19 REDONDO BEACH, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced its newest Southern California coastal community, Toll Brothers at Redondo Beach, is opening for sale. This exclusive community of 43 luxury townhomes is situated on Pacific Coast Highway in the heart of Redondo Beach’s South Bay coastal corridor. The offsite Sales Center, located at 101 N Pacific Coast Hwy Unit 102 in Redondo Beach, is opening this Saturday, September 19. Model homes are expected to open in early 2027, offering home shoppers the opportunity to take advantage of pre-model pricing. Toll Brothers at Redondo Beach presents a unique opportunity to own a luxurious new construction townhome in one...

Initial Advance of $2.5 Million to Realbotix LLC to Support Growth and Working Capital; Non-Interest Bearing Facility Is Automatically Cancelled and Discharged in Full Upon Closing of Pending Acquisition CINCINNATI, Ohio, Sept. 14, 2026 (GLOBE NEWSWIRE) — Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) today announced that it has provided a strategic bridge financing facility of up to $5,000,000 to Realbotix LLC (“Realbotix”), the target of its previously announced pending acquisition, to support Realbotix’s growth and working capital needs while the parties advance toward closing of the acquisition. The financing was provided in connection with the Share Exchange Agreement between the two companies, announced on February 12, 2026. The facility provides for an aggregate principal...

EVANSVILLE, Ind., Sept. 14, 2026 (GLOBE NEWSWIRE) — Old National Bank wants to make you aware of (and invite you to cover) our 5th annual Better Together Volunteer Days event.WHEN: September 16-17, 2026 (see attached document for locations and times by state)   WHAT: Two days of team-focused volunteerism serving non-profit organizations. Team members from across Old National’s footprint will be volunteering in four-hour shifts in the communities where they live and work.   WHO: More than 2,000 Old National team members, executives and clients   WHERE: Approximately 200 volunteer locations in ten states of Florida, Illinois, Iowa, Indiana, Kentucky, Michigan, Minnesota, North Dakota, Tennessee and Wisconsin (see attached document for times and locations)   WHY:  Better Together Days allows Old National...

Please see attached document.AttachmentPublic FAQs Reorganisation September 2026

(In accordance with article 5 of Regulation (EU) No 596/2014 on Market Abuse Regulation and article 3(3) of Delegated Regulation (EU) 2016/1052 supplementing Regulation (EU) No 596/2014 through regulatory technical standards concerning the conditions applicable to buyback programmes and stabilisation measures) As announced on Thursday 30 July 2026, Ayvens started on Friday 31 July 2026, an ordinary share buyback programme for a maximum amount of EUR 450 million for the purpose of shares cancellation. Ayvens received all necessary authorisations from supervisory authorities. The share buyback programme will be carried out in accordance with the provisions set out in the EU Regulation n°596/2014 of the European Parliament and of the Council of April 16th 2014, on market abuse, as modified, and its implementing provisions, and within the...

GENFIT’s acquisition of nangibotide, a differentiated late-stage asset, reinforces the Company’s portfolio of innovative therapies addressing high unmet medical needs The investigation in Phase 2 is supported by a robust scientific and clinical foundation around the TREM-1 pathway and the asset’s profile:Strong knowledge of nangibotide’s biological pathway Multiple efficacy signals already observed with nangibotide across three Phase 2 clinical trials in septic shock and COVID-19 subjects, including a statistically significant reduction in mortality in severe COVID-19 and significant improvements in SOFA score from baseline in septic shock Overall favorable safety and tolerability profile demonstrated across four clinical trials, with more than 400 subjects exposed to nangibotide, and no meaningful differences versus placebo...

The five shopping centres managed by Akropolis Group in Lithuania and Latvia welcomed 21.1 million visitors in the first half of the year, nearly 1% more than in the same period last year, while tenant turnover grew by 8.1% to EUR 604.1 million. With the results of Galio Group, the real estate development company acquired last year, included in Akropolis Group’s financial results since last October, the Group’s consolidated revenue grew by 29% to EUR 81.6 million in the first half of the year.  “Galio Group’s operating results had a significant impact on the sharp increase in the Group’s consolidated results, but we also delivered solid performance in the development of shopping and entertainment centres. Tenant turnover grew faster than inflation, while occupancy across our shopping centres in Lithuania and Latvia has already exceeded...

Company announcement No. 48 / 2026 Zealand Pharma – Transactions related to share buy-back program (week 37, 2026) Copenhagen, Denmark, September 14, 2026 – Zealand Pharma A/S (“the Company” or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the “Program”) for week 37 (September 7 – September 11, 2026). The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe Harbour Regulation”). Reference is made to company announcement no. 15 / 2026 dated May 7, 2026, which sets out the full terms of the Program. Under the Program, Zealand Pharma may repurchase...